Bioceres Crop Solutions Corp.

NasdaqGS:BIOX Lagerbericht

Marktkapitalisierung: US$399.7m

Bioceres Crop Solutions Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Bioceres Crop Solutions wird ein Gewinn- und Umsatzwachstum von 42.3% bzw. 9.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 40.7% pro Jahr wachsen soll.

Wichtige Informationen

42.3%

Wachstumsrate der Gewinne

40.7%

EPS-Wachstumsrate

Chemicals Gewinnwachstum16.8%
Wachstumsrate der Einnahmen9.6%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting

Nov 13

Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper

Sep 28
Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper

Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices

Sep 17

These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively

Aug 03
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively

Bioceres Needs To Add Clarity Around Borrowings

Mar 23

Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt

Feb 03
Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt

Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?

Oct 04
Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?

Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear

Jun 21
Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear

Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load

May 09
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load

Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings

Sep 06

Bioceres Crop Solutions jumps 15% after investor pitch

Aug 23

We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt

Apr 10
We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt

Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness

Mar 31

Is Now The Time To Look At Buying Bioceres Crop Solutions Corp. (NASDAQ:BIOX)?

Mar 17
Is Now The Time To Look At Buying Bioceres Crop Solutions Corp. (NASDAQ:BIOX)?

Is Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Trading At A 21% Discount?

Nov 13
Is Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Trading At A 21% Discount?

Bioceres Crop Solutions (NASDAQ:BIOX) Shareholders Will Want The ROCE Trajectory To Continue

Jul 08
Bioceres Crop Solutions (NASDAQ:BIOX) Shareholders Will Want The ROCE Trajectory To Continue

Estimating The Intrinsic Value Of Bioceres Crop Solutions Corp. (NASDAQ:BIOX)

Jun 16
Estimating The Intrinsic Value Of Bioceres Crop Solutions Corp. (NASDAQ:BIOX)

What Does Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Share Price Indicate?

May 26
What Does Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Share Price Indicate?

Bioceres partners with Havanna to offer consumers HB4 wheat-based sustainable products

May 10

Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?

May 05
Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?

Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Will Want The ROCE Trajectory To Continue

Apr 05
Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Will Want The ROCE Trajectory To Continue

Are Investors Undervaluing Bioceres Crop Solutions Corp. (NYSEMKT:BIOX) By 22%?

Mar 10
Are Investors Undervaluing Bioceres Crop Solutions Corp. (NYSEMKT:BIOX) By 22%?

Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Booked A 53% Gain In The Last Year

Feb 12
Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Booked A 53% Gain In The Last Year

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BIOX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/20275715532N/A1
6/30/20265112951N/A3
6/30/20254631149N/A4
9/30/20244412N/AN/AN/A
6/30/202446531942N/A
3/31/20244463-1310N/A
12/31/202345522630N/A
9/30/2023409142650N/A
6/30/202341919-203N/A
3/31/202341615-126N/A
12/31/2022391-19-311N/A
9/30/2022389-8-47-36N/A
6/30/2022328-7-27-18N/A
3/31/2022308-2-19N/A
12/31/20212754-12-2N/A
9/30/20212311-27-12N/A
6/30/2021207-7-20-6N/A
3/31/2021174-5-36-24N/A
12/31/2020164-7-24-13N/A
9/30/20201783-9-4N/A
6/30/2020172359N/A
3/31/202017401418N/A
12/31/2019167-182832N/A
9/30/2019167-231822N/A
6/30/2019160-182630N/A
3/31/2019142-262933N/A
12/31/2018145-82227N/A
9/30/2018129-133137N/A
6/30/2018133-11N/A18N/A
6/30/201794-12N/A19N/A
12/31/201641-6N/A-1N/A
12/31/20155-1N/A-1N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIOXDas prognostizierte Gewinnwachstum (42.3% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: BIOXDie Erträge des Unternehmens (42.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: BIOXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: BIOXDie Einnahmen des Unternehmens (9.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: BIOXDie Einnahmen des Unternehmens (9.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BIOX in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y